Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes

New results from the OMICS study, which will be presented atASCO, show Universal DX`s blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening

Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ranging between S30B and S75B in the U.S. alone

(JUNE 3, 2021) CAMBRIDGE, MA. - Universal Diagnostics (UDX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced the results of an international multicenter observational cohort study: Colorectal cancer detection at 92% sensitivity and 97% specificity was achieved using single targeted sequencing analysis of multi-omics markers, advanced computational biology and machine learning algorithms. The company`s approach also demonstrates high levels of accurate detection of early-stage (I, II) colorectal cancer at 89% sensitivity and 97% specificity.

Universal DX is specially focused on identifying cancer in its earliest stages, so that the disease can be cured, and even in its pre-cancerous stage, when cancer can be prevented. The company leverages proprietary, state-of-the-art computational biology tools combined with targeted next generation sequencing (NGS) assay platform for highly sensitive cancer signal scoring of cell-free DNA regions linked to cancer of interest. The company is developing "Signal-X", a platform to detect multiple types of cancer; its first product, "Signal-C", detects early-stage colorectal cancer and adenomatous polyps.

"We have built a test that can "read" cancer`s tissue-specific signal in blood on a fragment level," said Christian Hense, managing director at Universal DX. "We know that if we can detect cancer early, or identify pre-cancer stage patients before they develop cancer, the survival rates increase exponentially. In order to do that, we need to develop new screening methods that are simple, non-invasive, accurate, and more accessible and affordable than what`s available today. At Universal DX, we are driven by the belief that cancer can be a curable disease, and continue to work tirelessly to develop blood-based tools that can make that a reality."